Oxford-AstraZeneca Vaccine for COVID-19: A Case Report: COVID-19

Authors

Mehdi Pooladi1,*, Soheila Karani2
1Cellular and Molecular Biology-Biophysics, university of science and research, Azad university, Tehran (Iran)
2Department of Biology, School of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran.
*Corresponding Author: Cellular and Molecular Biology-Biophysics, university of science and research, Azad university, Tehran (Iran) Email: [email protected]

Journal of Cellular & Molecular Anesthesia:Vol. 6, issue 4; e149734
Published online:Sep 07, 2021
Article type:Case Report
How to Cite:Pooladi M, Karani S. Oxford-AstraZeneca Vaccine for COVID-19: A Case Report: COVID-19. J Cell Mol Anesth. 2021;6(4):e149734. doi: https://doi.org/10.22037/jcma.v6i4.34860

Abstract

The design and development of a vaccine against the new coronavirus obtain an important goal of the global health community, which has developed and approved several vaccines, including the Oxford-AstraZeneca vaccine. The vaccine has been challenged because of reports of side effects after vaccination, while the level of immunity created by the vaccine has been confirmed. In this study, we examined the complication and change in laboratory tests of hematology, biochemistry, and enzymology in a 42-year-old woman with no history of specific disease after receiving the Oxford-AstraZeneca vaccine for 7 days. Our studies showed that following the injection of the vaccine, platelet, RBC, WBC decreased, and increased D-Dimer rates. Also that the standard rate has changed between Neutrophil, Lymphocyte, and Monocyte. There is evidence of Prothrombotic Immune Thrombocytopenia and following that there is a risk of the embolism, but the particular point is that this complication is temporary and the test process is progressing towards recovery.

References

  • 1.
    References are in the PDF file of the article.

Copyright

© 2021, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Oct
2022
Spontaneous Subarachnoid Haemorrhage After COVID-19 Vaccination; a Rare Case Report

Spontaneous Subarachnoid Haemorrhage After COVID-19 Vaccination; a Rare Case Report

Mostafa Abdollahi,
Nasim Alidaei,
Ayoub Ayar

Abdollahi M, Alidaei N, Ayar A. Spontaneous Subarachnoid Haemorrhage After COVID-19 Vaccination; a Rare Case Report. Arch Clin Infect Dis. 2022;17(5):e127354. doi: https://doi.org/10.5812/archcid-127354

10
Nov
2022
A Comparison of Adverse Reactions of the First Dose of Gam-COVID-vac (Sputnik V), Oxford/AstraZeneca COVID-19 Vaccine, Bharat Biotech (Covaxin), and (Sinopharm) BBIBP-CorV Vaccines

A Comparison of Adverse Reactions of the First Dose of Gam-COVID-vac (Sputnik V), Oxford/AstraZeneca COVID-19 Vaccine, Bharat Biotech (Covaxin), and (Sinopharm) BBIBP-CorV Vaccines

HamidReza Samimagham,
Mehdi Hassani Azad,
Mohsen Arabi,
Sobhan Montazer Ghaem,
Kimiya Jafari,
Dariush Hooshyar
,et al.

Samimagham H, Hassani Azad M, Arabi M, Montazer Ghaem S, Jafari K, et al. A Comparison of Adverse Reactions of the First Dose of Gam-COVID-vac (Sputnik V), Oxford/AstraZeneca COVID-19 Vaccine, Bharat Biotech (Covaxin), and (Sinopharm) BBIBP-CorV Vaccines. J Health Rep Technol. 2022;8(4):e122479. doi: https://doi.org/10.5812/jhrt-122479

1
Jun
2022
Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-Year-Old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report

Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-Year-Old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report

Elham Ramezanzade,
Reyhane Ghanbari,
Tina Yazdanipour

Ramezanzade E, Ghanbari R, Yazdanipour T. Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-Year-Old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report. Nephro-Urol Mon. 2022;14(3):e127124. doi: https://doi.org/10.5812/numonthly-127124

30
Jun
2021

The Alteration of Clinical and Laboratory Signs and Symptoms of COVID-19 in Re-infection: A Case Report

leili yekefallah,
Peyman Namdar,
sareh mohammadi

yekefallah L, Namdar P, mohammadi S. The Alteration of Clinical and Laboratory Signs and Symptoms of COVID-19 in Re-infection: A Case Report. J Inflamm Dis. 2024;25(1):e156265. doi:

28
Dec
2024
Vaccination Against COVID-19 in Comorbid Patients

Vaccination Against COVID-19 in Comorbid Patients

Maira Ashirova Ashirova,
Gulzhan Narkenovna Abuova,
Gulbanu Ganikyzy Shaimerdenova

Ashirova Ashirova M, Abuova GN, Shaimerdenova GG. Vaccination Against COVID-19 in Comorbid Patients. Arch Clin Infect Dis. 2025;20(1):e148021. doi: https://doi.org/10.5812/archcid-148021

More by these authors

Mehdi PooladiPubMedScholar
Soheila KaraniPubMedScholar
Share
Cited by
Metrics